IMI AMR ACCELERATOR

We’re live at the AMR Conference in Basel — come meet us today!

📍 Machine Learning for Gram-negative Permeability (Frederik Deroose)
📍 Improving Translational Pneumonia Models (Carina Vingsbo-Lundberg)

💬 Stop by the posters, say hello, and explore collaboration opportunities.

If you have data that could fit the open call, fill in this form to get in contact with the researchers: forms.office.com/e/YMs09w27ce

📢 Call for Data: Help Advance Antibiotic Discovery Against Gram-Negative Bacteria!

The AMR Accelerator Scientific Interest Group on Machine Learning is building a predictive model for membrane permeability in Gram-negative bacteria — and we need your support.
Link to the survey in first comment 👇

Meet us at the AMR Conference 2026! - IMI AMR Accelerator

Find out more about the research and the people behind it: amr-accelerator.eu/news/meet-us...

Meet us at the AMR Conference in Basel today and tomorrow!

🧠 Researchers from different projects of the accelerator are presenting posters on
Machine Learning for Gram-negative permeability
🧪 Advancing TB drug development with HFS-TB
🫁 The COMBINE Pneumonia Model

Will you be there? Get connected!

About us - IMI AMR Accelerator The AMR Accelerator is an IMI Programme that progresses the development of new medicines to treat or prevent resistant bacterial infections, aiming to deliver 10 preclinical or clinical candidates and...

For more infos on publications, tools & resources, project portfolios and a lot more, visit the AMR Accelerator website:
amr-accelerator.eu

Characterization of Two Novel Inhibitors of the Mycobacterium tuberculosis Cytochrome bc1 Complex | Antimicrobial Agents and Chemotherapy Drug-resistant tuberculosis is a global health care threat calling for novel effective treatment options. Here, we report on two novel cytochrome bc1 inhibitors (MJ-22 and B6) targeting the Mycobacterium tuberculosis respiratory chain with excellent intracellular activities in human macrophages. Both hit compounds revealed very low mutation frequencies and distinct cross-resistance patterns with other advanced cytochrome bc1 inhibitors.

Link to the study 👉 journals.asm.org/doi/10.1128/...

𝗘𝘅𝗽𝗮𝗻𝗱𝗶𝗻𝗴 𝘁𝗵𝗲 𝗧𝗕 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗣𝗶𝗽𝗲𝗹𝗶𝗻𝗲

Today we highlight a study published by ERA4TB. It contributes to a growing pipeline of compounds designed to tackle drug-resistant TB through novel mechanisms and strategies.

𝗪𝗵𝗮𝘁 𝗪𝗲 𝗗𝗶𝗱. 𝗪𝗵𝘆 𝗜𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀. 𝗪𝗵𝗲𝗿𝗲 𝗜𝘁 𝗟𝗲𝗮𝗱𝘀. 👇

𝗥𝗲𝘃𝗶𝘀𝗶𝘁𝗶𝗻𝗴 𝗧𝗕 𝗣𝗵𝘆𝘀𝗶𝗼𝗽𝗮𝘁𝗵𝗼𝗹𝗼𝗴𝘆
A study published by members of our project ERA4TB uncovers how 𝘔𝘺𝘤𝘰𝘣𝘢𝘤𝘵𝘦𝘳𝘪𝘶𝘮 𝘵𝘶𝘣𝘦𝘳𝘤𝘶𝘭𝘰𝘴𝘪𝘴 forms tightly biofilm-like cords that dramatically alter its interaction with the immune system.

𝗪𝗵𝗮𝘁 𝗪𝗲 𝗗𝗶𝗱. 𝗪𝗵𝘆 𝗜𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀. 𝗪𝗵𝗲𝗿𝗲 𝗜𝘁 𝗟𝗲𝗮𝗱𝘀. 👇

#amr #tuberculosis #antibiotics

Mechanopathology of biofilm-like Mycobacterium tuberculosis cords Energy storage in the cell membrane, made possible by the compression of cell surface lipids, enables individual Mycobacterium tuberculosis to grow into high-aspect-ratio mechanically resilient suprac...

Link to the study: www.cell.com/cell/fulltex...

Learn more about the AMR Accelerator on amr-accelerator.eu

𝗥𝗲𝘃𝗶𝘀𝗶𝘁𝗶𝗻𝗴 𝗧𝗕 𝗣𝗵𝘆𝘀𝗶𝗼𝗽𝗮𝘁𝗵𝗼𝗹𝗼𝗴𝘆
A study published by members of our project ERA4TB uncovers how 𝘔𝘺𝘤𝘰𝘣𝘢𝘤𝘵𝘦𝘳𝘪𝘶𝘮 𝘵𝘶𝘣𝘦𝘳𝘤𝘶𝘭𝘰𝘴𝘪𝘴 forms tightly biofilm-like cords that dramatically alter its interaction with the immune system.

𝗪𝗵𝗮𝘁 𝗪𝗲 𝗗𝗶𝗱. 𝗪𝗵𝘆 𝗜𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀. 𝗪𝗵𝗲𝗿𝗲 𝗜𝘁 𝗟𝗲𝗮𝗱𝘀. 👇

#amr #tuberculosis #antibiotics

Hear from Marie Attwood (@reepkpd333.bsky.social) in an exclusive interview about her work in using 𝘪𝘯 𝘷𝘪𝘵𝘳𝘰 models in AMR research as a GNA NOW PK/PD expert.

She offers insights into:
🔬 Decade of progression
🧫 Hollow-fibre modelling
🦠 AI-driven discovery

🔗 https://bit.ly/4plTnqW

We are excited to share the latest work under RespiriTB, published in Nature Communications! The study explores how targeting the M. tuberculosis cytochrome bc1 complex could unlock new treatment options for both DS-TB & MDR-TB.

👉 https://go.nature.com/48cWgEV

How can we speed up TB clinical trials efficiently? Our latest work led by global TB experts, under UNITE4TB defines the ideal biomarker assays to reliably track treatment response, therefore helping trials be faster, smarter and more effective.

👉 Read at: https://bit.ly/4iVmPAu

𝗨𝗻𝗺𝗮𝘀𝗸𝗶𝗻𝗴 𝗛𝗼𝘀𝘁–𝗣𝗮𝘁𝗵𝗼𝗴𝗲𝗻 𝗜𝗻𝘁𝗲𝗿𝗮𝗰𝘁𝗶𝗼𝗻𝘀 𝗶𝗻 𝗧𝗕

Today we showcase a study by our project ERA4TB revealing a previously underappreciated mechanism by which 𝘔𝘺𝘤𝘰𝘣𝘢𝘤𝘵𝘦𝘳𝘪𝘶𝘮 𝘵𝘶𝘣𝘦𝘳𝘤𝘶𝘭𝘰𝘴𝘪𝘴 aggregates kill macrophages without being taken up by them.

𝗪𝗵𝗮𝘁 𝗪𝗲 𝗗𝗶𝗱. 𝗪𝗵𝘆 𝗜𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀. 𝗪𝗵𝗲𝗿𝗲 𝗜𝘁 𝗟𝗲𝗮𝗱𝘀. 👇

𝗨𝗻𝗺𝗮𝘀𝗸𝗶𝗻𝗴 𝗛𝗼𝘀𝘁–𝗣𝗮𝘁𝗵𝗼𝗴𝗲𝗻 𝗜𝗻𝘁𝗲𝗿𝗮𝗰𝘁𝗶𝗼𝗻𝘀 𝗶𝗻 𝗧𝗕

Today we showcase a study by our project ERA4TB revealing a previously underappreciated mechanism by which 𝘔𝘺𝘤𝘰𝘣𝘢𝘤𝘵𝘦𝘳𝘪𝘶𝘮 𝘵𝘶𝘣𝘦𝘳𝘤𝘶𝘭𝘰𝘴𝘪𝘴 aggregates kill macrophages without being taken up by them.

𝗪𝗵𝗮𝘁 𝗪𝗲 𝗗𝗶𝗱. 𝗪𝗵𝘆 𝗜𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀. 𝗪𝗵𝗲𝗿𝗲 𝗜𝘁 𝗟𝗲𝗮𝗱𝘀. 👇

Today is the International Day of Women and Girls in Science, and we're shining the spotlight on Ariane Bollack, who took part in the AMYPAD project as a PhD student. We asked her how taking part in the PPP shaped her career.

♀️ Today is the #InternationalDayofWomenandGirlsinScience! 🧠 Meet Ariane Bollack, a former PhD student from the AMYPAD project who's now working in industry. We asked her how the PPP shaped her career & what advice she has for young researchers 👉 link.europa.eu/K6GPPp
#WomenInScience #WomenInSTEM

In this latest study under @era4tb.bsky.social, researchers adopted physiologically‑based pharmacokinetic (PBPK) modelling and used a detailed computational model to project what those concentrations likely are in human lungs (both healthy and TB-infected).

👉 Read at: https://bit.ly/3KA2RQx

Hear from Pedro Quintela in an interview about his work in GNA NOW advancing 𝘪𝘯 𝘷𝘪𝘷𝘰 proof-of-concept models for AMR research.

He shares insights into:
🦠 Broader pathogen coverage
🤝 Interdisciplinary collaboration
💡 Championing the promise of each experiment

https://bit.ly/49Hdtr1

The role of cytochrome bc1 inhibitors in future tuberculosis treatment regimens - Nature Communications The cytochrome bc1 oxidase of Mycobacterium tuberculosis is a potential target in the fight against tuberculosis. Here, the authors evaluate the potential of cytochrome bc1 inhibitors as partner drugs...

Link to the study: www.nature.com/articles/s41...

The COMBINE pneumonia model: a multicenter study to standardize a mouse pneumonia model with Pseudomonas aeruginosa and Klebsiella pneumoniae for antibiotic development | Microbiology Spectrum The rise of antibiotic-resistant bacteria has made it increasingly difficult to treat common infections, such as pneumonia. To develop new antibiotics, scientists rely on animal infection models to te...

Link to the publication: journals.asm.org/doi/10.1128/...

COMBINE Pneumonia Model by AMR Accelerator Project

𝗧𝗵𝗲 𝗖𝗢𝗠𝗕𝗜𝗡𝗘 𝗣𝗻𝗲𝘂𝗺𝗼𝗻𝗶𝗮 𝗠𝗼𝗱𝗲𝗹: 𝗡𝗲𝘄 𝘁𝗼𝗼𝗹𝘀 𝗳𝗼𝗿 𝗮𝗻𝘁𝗶𝗯𝗶𝗼𝘁𝗶𝗰 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗮𝗴𝗮𝗶𝗻𝘀𝘁 𝗱𝗿𝘂𝗴-𝗿𝗲𝘀𝗶𝘀𝘁𝗮𝗻𝘁 𝗽𝗻𝗲𝘂𝗺𝗼𝗻𝗶𝗮

𝗡𝗼𝘄 𝗽𝘂𝗯𝗹𝗶𝘀𝗵𝗲𝗱 𝗶𝗻 𝗠𝗶𝗰𝗿𝗼𝗯𝗶𝗼𝗹𝗼𝗴𝘆 𝗦𝗽𝗲𝗰𝘁𝗿𝘂𝗺, this framework is openly available to academia, CROs, and industry. A real enabler for accelerating antibiotics against WHO-listed critical pathogens. #AMR

🚨 The AMR Accelerator needs your help! Our Machine Learning group seeks datasets to build a Gram-negative permeability prediction model.
𝗜𝗳 𝘆𝗼𝘂 𝗵𝗮𝘃𝗲 𝘀𝘂𝗶𝘁𝗮𝗯𝗹𝗲 𝗱𝗮𝘁𝗮𝘀𝗲𝘁𝘀, 𝗽𝗹𝗲𝗮𝘀𝗲 𝘃𝗶𝘀𝗶𝘁: https://bit.ly/4piUvMw

Fill out a form and we will contact you!

𝗘𝗻𝗴𝗶𝗻𝗲𝗲𝗿𝗶𝗻𝗴 𝗡𝗲𝘅𝘁-𝗚𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗧𝗕 𝗥𝗲𝗴𝗶𝗺𝗲𝗻𝘀

Today we highlight a study from the RespiriTB project, published in Nature Communications investigating cytochrome bc₁ inhibitors as novel partners in tuberculosis combination therapy.

Find out 𝗪𝗵𝗮𝘁 𝗪𝗲 𝗗𝗶𝗱. 𝗪𝗵𝘆 𝗜𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀. 𝗪𝗵𝗲𝗿𝗲 𝗜𝘁 𝗟𝗲𝗮𝗱𝘀. 👇

Medical product manufacturing in the EU

🏭 IMI & IHI projects are helping to make the manufacture of medical products in Europe better, faster & cheaper, boosting #EUCompetitiveness & strengthening #HealthResilience - find out how:👉 lnkd.in/eFczWHw2
#IHITransformingHealth #HealthUnion #MedicinesManufacture #MedicalDevices #MedTech

How can we speed up TB clinical trials efficiently? Our latest work led by global TB experts, under UNITE4TB defines the ideal biomarker assays to reliably track treatment response, therefore helping trials be faster, smarter and more effective.

👉 Read at: https://bit.ly/4iVmPAu

✨ With 2025 coming to an end, we at the AMR Accelerator are taking a moment to thank all our projects, partners, researchers and supporters. Wishing everyone of you a warm holiday season and see you again in 2026, where our story continues....

In our latest study under RespiriTB, researchers developed a fast “screening factory” to test hundreds of compounds against a key TB enzyme, mycothione reductase, which is crucial bacterial survival mechanism.

👉 𝗥𝗲𝗮𝗱 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲 𝗽𝗮𝗽𝗲𝗿 𝗮𝘁: https://bit.ly/4orDHl4

Hear from Pedro Quintela in an interview about his work in GNA NOW advancing 𝘪𝘯 𝘷𝘪𝘷𝘰 proof-of-concept models for AMR research.

He shares insights into:
🦠 Broader pathogen coverage
🤝 Interdisciplinary collaboration
💡 Championing the promise of each experiment

https://bit.ly/49Hdtr1

In this latest study under @era4tb.bsky.social, researchers adopted physiologically‑based pharmacokinetic (PBPK) modelling and used a detailed computational model to project what those concentrations likely are in human lungs (both healthy and TB-infected).

👉 Read at: https://bit.ly/3KA2RQx